Skip to main content
. 2020 Feb 24;130(4):1635–1652. doi: 10.1172/JCI129497

Figure 9. NLRX1-potentiated tumor immune escape is IFN-I–dependent.

Figure 9

(A) C57BL/6 hosts were given 0.5 mg of anti-CD8 or PBS intraperitoneally daily for 3 days before the tumor implantation and then twice per week for 2 weeks. The overall tumor burden was compared using the generalized estimating equations model (n = 7 in each group; *P < 0.05). (B) Tumors were harvested and total RNA isolated for qPCR detection of the indicated STING signature genes. Values represent mean ± SEM. Comparisons between groups were assessed using an unpaired t test. (C) One million EV control or shNLRX1 MOC2-E6/E7 cells were inoculated subcutaneously in the right flank of Rag1–/– mice. Tumors were monitored and compared as described above (n = 6 in each group). (D) After euthanasia, tumors were harvested and total RNA was isolated. qPCR was conducted to quantify the mRNA levels of indicated genes. Values represent mean ± SEM. Comparisons between groups were assessed using an unpaired t test. (E) One million EV control or shNLRX1 MOC2-E6/E7 cells were inoculated subcutaneously in the right flank of Ifnar1–/– mice (n = 5 in control group, n = 6 in shNLRX1 group). Tumor growth was monitored and compared as described above. Experiments were performed twice, and 1 representative set is shown. (F) After euthanasia, all tumors were harvested and total RNA isolated for qPCR analysis. Values represent mean ± SEM. Comparisons between groups were assessed using an unpaired t test.